|Security||ARGS / Argos Therapeutics, Inc.|
|Institution||Two Sigma Securities, Llc|
Two Sigma Securities, Llc closes passive position in ARGS / Argos Therapeutics, Inc.
May 15, 2018 - Two Sigma Securities, Llc has filed a 13F-HR form disclosing ownership of 0 shares of Argos Therapeutics, Inc. (OTC:ARGS) with total holdings valued at $0 USD as of March 31, 2018. Two Sigma Securities, Llc had filed a previous 13F-HR on February 14, 2018 disclosing 47,961 shares of Argos Therapeutics, Inc. at a value of $7,000 USD. This represents a change in shares of -100.00 percent and a change in value of -100.00 percent during the quarter.
Argos Therapeutics, Inc. has declared a standard industrial code (sic) of 2834 which is the "Pharmaceutical Preparations" industry. Two Sigma Securities, Llc's top industries are "Agricultural Services" (sic 07), "Heavy Construction Other Than Building Construction Contractors" (sic 16), and "Construction Special Trade Contractors" (sic 17).
The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.
In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.
Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.
2017-11-08 - Asif
Argos Therapeutics is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary precision immunotherapy technology platform called Arcelis. The company's most advanced product candidate is rocapuldencel-T, which Argos Therapeutics is developing for the treatment of metastatic renal cell carcinoma, or mRCC, and other cancers. Argos Therapeutics is currently conducting a pivotal Phase 3 clinical trial of rocapuldencel-T plus sunitinib or another therapy for the treatment of newly diagnosed mRCC under a special protocol assessment, or SPA, with the Food and Drug Administration, or FDA. The company refer to this trial as the ADAPT trial. The company dosed the first patient in the ADAPT trial in May 2013 and completed enrollment of the ADAPT trial in July 2015. In February 2017, the independent data monitoring committee, or the IDMC, for the ADAPT trial recomm...
as of ET